Author
Listed:
- Haiyang Yu
(Rutgers Cancer Institute of New Jersey, Rutgers, the State University of New Jersey)
- Xuetian Yue
(Rutgers Cancer Institute of New Jersey, Rutgers, the State University of New Jersey)
- Yuhan Zhao
(Rutgers Cancer Institute of New Jersey, Rutgers, the State University of New Jersey)
- Xiaoyan Li
(Rutgers Cancer Institute of New Jersey, Rutgers, the State University of New Jersey
Qilu Hospital, Shandong University)
- Lihua Wu
(Rutgers Cancer Institute of New Jersey, Rutgers, the State University of New Jersey
First Affiliated Hospital, Zhejiang University)
- Cen Zhang
(Rutgers Cancer Institute of New Jersey, Rutgers, the State University of New Jersey)
- Zhen Liu
(Rutgers Cancer Institute of New Jersey, Rutgers, the State University of New Jersey)
- Kevin Lin
(Rutgers Cancer Institute of New Jersey, Rutgers, the State University of New Jersey)
- Zijun Y. Xu-Monette
(University of Texas MD Anderson Cancer Center)
- Ken H. Young
(University of Texas MD Anderson Cancer Center)
- Juan Liu
(Rutgers Cancer Institute of New Jersey, Rutgers, the State University of New Jersey)
- Zhiyuan Shen
(Rutgers Cancer Institute of New Jersey, Rutgers, the State University of New Jersey)
- Zhaohui Feng
(Rutgers Cancer Institute of New Jersey, Rutgers, the State University of New Jersey)
- Wenwei Hu
(Rutgers Cancer Institute of New Jersey, Rutgers, the State University of New Jersey)
Abstract
Leukaemia inhibitory factor (LIF) has been recently identified as a p53 target gene, which mediates the role of p53 in maternal implantation under normal physiological conditions. Here we report that LIF is a negative regulator of p53; LIF downregulates p53 protein levels and function in human colorectal cancer (CRC) cells. The downregulation of p53 by LIF is mediated by the activation of Stat3, which transcriptionally induces inhibitor of DNA-binding 1 (ID1). ID1 upregulates MDM2, a key negative regulator of p53, and promotes p53 protein degradation. LIF is overexpressed in a large percentage of CRCs. LIF overexpression promotes cellular resistance towards chemotherapeutic agents in cultured CRC cells and colorectal xenograft tumours in a largely p53-dependent manner. Overexpression of LIF is associated with a poor prognosis in CRC patients. Taken together, LIF is a novel negative regulator of p53, overexpression of LIF is an important mechanism for the attenuation of p53, which promotes chemoresistance in CRCs.
Suggested Citation
Haiyang Yu & Xuetian Yue & Yuhan Zhao & Xiaoyan Li & Lihua Wu & Cen Zhang & Zhen Liu & Kevin Lin & Zijun Y. Xu-Monette & Ken H. Young & Juan Liu & Zhiyuan Shen & Zhaohui Feng & Wenwei Hu, 2014.
"LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers,"
Nature Communications, Nature, vol. 5(1), pages 1-12, December.
Handle:
RePEc:nat:natcom:v:5:y:2014:i:1:d:10.1038_ncomms6218
DOI: 10.1038/ncomms6218
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:5:y:2014:i:1:d:10.1038_ncomms6218. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.